Bridges Investment Management Inc. grew its stake in Colgate-Palmolive (NYSE:CL) by 11.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,715 shares of the company’s stock after purchasing an additional 2,765 shares during the quarter. Bridges Investment Management Inc.’s holdings in Colgate-Palmolive were worth $2,091,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of CL. Beach Investment Management LLC. bought a new position in shares of Colgate-Palmolive in the second quarter valued at approximately $3,954,000. Willingdon Wealth Management lifted its holdings in shares of Colgate-Palmolive by 1.1% in the second quarter. Willingdon Wealth Management now owns 28,048 shares of the company’s stock valued at $2,079,000 after purchasing an additional 312 shares in the last quarter. Airain ltd bought a new position in shares of Colgate-Palmolive in the second quarter valued at approximately $653,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Colgate-Palmolive by 17.8% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 167,306 shares of the company’s stock valued at $12,402,000 after purchasing an additional 25,241 shares in the last quarter. Finally, BDO Wealth Advisors LLC bought a new position in shares of Colgate-Palmolive in the second quarter valued at approximately $266,000. Institutional investors own 71.52% of the company’s stock.
Shares of Colgate-Palmolive (CL) opened at $70.30 on Friday. The company has a debt-to-equity ratio of 27.02, a current ratio of 1.36 and a quick ratio of 1.00. Colgate-Palmolive has a 52-week low of $68.19 and a 52-week high of $77.91. The stock has a market capitalization of $61,540.00, a price-to-earnings ratio of 27.14, a price-to-earnings-growth ratio of 2.57 and a beta of 0.75.
Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, January 26th. The company reported $0.75 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.75. Colgate-Palmolive had a return on equity of 1,716.69% and a net margin of 13.10%. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period last year, the business posted $0.75 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. equities analysts predict that Colgate-Palmolive will post 3.18 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 15th. Shareholders of record on Tuesday, January 23rd were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date was Monday, January 22nd. Colgate-Palmolive’s dividend payout ratio is currently 61.78%.
In other Colgate-Palmolive news, CTO Patricia Verduin sold 1,572 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $70.17, for a total value of $110,307.24. Following the completion of the sale, the chief technology officer now directly owns 50,675 shares of the company’s stock, valued at $3,555,864.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Daniel B. Marsili sold 5,692 shares of the firm’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $70.19, for a total value of $399,521.48. Following the completion of the sale, the insider now directly owns 41,677 shares of the company’s stock, valued at $2,925,308.63. The disclosure for this sale can be found here. Insiders sold 463,082 shares of company stock valued at $32,983,130 over the last three months. Company insiders own 1.02% of the company’s stock.
A number of brokerages recently commented on CL. Zacks Investment Research upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a report on Monday, January 8th. Jefferies Group dropped their price target on Colgate-Palmolive from $79.00 to $76.00 and set a “hold” rating on the stock in a report on Monday, October 30th. Stifel Nicolaus set a $73.00 price target on Colgate-Palmolive and gave the stock a “hold” rating in a report on Sunday, October 29th. Deutsche Bank began coverage on Colgate-Palmolive in a report on Wednesday, December 13th. They set a “hold” rating and a $75.00 price target on the stock. Finally, KeyCorp reiterated a “hold” rating on shares of Colgate-Palmolive in a report on Saturday, November 25th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $77.91.
TRADEMARK VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/25/bridges-investment-management-inc-buys-2765-shares-of-colgate-palmolive-cl.html.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.